RE: Price Gainers

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Pursuant to a resolution passed by shareholders on Dec. 20, 2012, Stem Cell Therapeutics Corp. has consolidated its capital on a 1:10 basis. The name of the company has not been changed.

Effective at the opening on Wednesday, Feb. 6, 2013, the shares of Stem Cell Therapeutics will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a scientific research and development services company.